Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.

被引：20

作者：

Kelley, Robin Kate

Cheng, Ann-Lii

Braiteh, Fadi S.

Park, Joong-Won

Benzaghou, Fawzi

Milwee, Steven

Borgman, Anne

El-Khoueiry, Anthony B.

Kayali, Zeid K.

Zhu, Andrew X.

Rimassa, Lorenza

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[2] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[3] Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA

[4] Natl Canc Ctr Korea, Goyang Si, South Korea

[5] IPSEN, Paris, France

[6] Exelixis Inc, San Francisco, CA USA

[7] Exelixis, Alameda, CA USA

[8] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[9] Riverside Community Hosp, Rialto, CA USA

[10] Harvard Med Ctr, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[11] IRCCS, Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Med Oncol & Hematol Unit, Rozzano, Italy

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS4157

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4157

引用

页数：2